Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

118.10CHF
24 Apr 2015
Change (% chg)

CHF3.60 (+3.14%)
Prev Close
CHF114.50
Open
CHF115.70
Day's High
CHF119.20
Day's Low
CHF115.30
Volume
133,728
Avg. Vol
75,732
52-wk High
CHF125.50
52-wk Low
CHF79.75

BSLN.S

Chart for BSLN.S

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.93
Market Cap(Mil.): CHF1,262.22
Shares Outstanding(Mil.): 10.69
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 159.31 41.69
EPS (TTM): -4.19 -- --
ROI: -19.10 -0.90 16.15
ROE: -64.51 -2.84 16.96
Search Stocks

BRIEF-Basilea Pharmaceutica in-licenses targeted cancer therapy

* Entered into license agreement for novel panRAF kinase inhibitors with consortium of organizations including Institute Of Cancer Research, London, Cancer Research Technology, Wellcome Trust and University Of Manchester Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Apr 2015

BRIEF-Basilea Pharmaceutica FY 2014 total operating income CHF 42.6 mln vs CHF 41.4 mln yr ago

* Says FY 2014 net loss of 41.5 million Swiss francs($44.53 million)

17 Feb 2015

BRIEF-Basilea Pharmaceutica says Swissmedic approves Zevtera

* Says Swissmedic approves Basilea's antibiotic Zevtera (ceftobiprole medocaril) for treatment of pneumonia

22 Dec 2014

BRIEF-Basilea Pharmaceutica announces launch of antibiotic Zevtera in Germany

* Announces launch of antibiotic Zevtera (ceftobiprole medocaril) in Germany Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Dec 2014

BRIEF-Basilea Pharmaceutica gets U.S. orphan drug designation for isavuconazole for treatment of invasive candidiasis

* Reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis

03 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks